Price movement over the last 24 hours
Agilent Technologies Inc vs Oxford Lane Capital Corp — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Oxford Lane Capital Corp trades at $9.07 (market cap $872.99M). The key difference: Agilent Technologies Inc is far larger — about 42.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.85%). Which is the better fit depends on your goals.
| A | OXLC | |
|---|---|---|
Market Cap | $37.04B | $872.99M |
Sector | Health | Financials |
52-Week High | $157.20 | $20.80 |
52-Week Low | $110.24 | $8.15 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 26.85% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
OXLC trades at $8.95, up 1.59% today, with a bullish technical signal but mixed indicators. The stock shows a P/B of 0.85, suggesting potential undervaluation, but profitability metrics are weak with a -39.16% ROE. Recent earnings have consistently missed expectations, including a significant Q1 2026 EPS miss. The company maintains a regular dividend payout of $0.20 per share, supporting income-focused investors despite fundamental challenges.
Outlook remains cautious due to persistent earnings underperformance and negative ROE/ROA. High dividend yield attracts income seekers, but sustainability concerns and NAV declines pose risks. Analyst consensus is divided, with 50% buy ratings balanced by bearish sentiment from financial media. Key risks include further NAV erosion and reliance on financing cash flows.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →